What are the adverse effects of capivasertib (AKT inhibitor) and the recommended monitoring and management?

Capivasertib Adverse Effects and Management

Capivasertib causes three major adverse effects requiring proactive monitoring: hyperglycemia (57% any grade), diarrhea (72%, 9% grade 3-4), and cutaneous reactions (58%, 17% grade 3-4), with hyperglycemia being the most dangerous as it can rapidly progress to diabetic ketoacidosis within days of treatment initiation. 1

Hyperglycemia - The Most Critical Adverse Effect

Incidence and Timing

• 57% of patients develop elevated random glucose, 37% elevated fasting glucose 1
• Onset occurs within 2 weeks, often within 4 days of starting treatment 2, 3
• Can progress to diabetic ketoacidosis requiring immediate permanent discontinuation 1
• Follows a distinctive pattern synchronized with the 4-days-on/3-days-off dosing cycle 2, 4

Mechanism

Capivasertib-induced hyperglycemia results from AKT pathway inhibition causing severe insulin resistance with impaired glucose uptake and dysregulated hepatic glucose output 4, 5. Notably, pancreatic β-cell function is typically preserved, with markedly elevated insulin levels (up to 591.9 μU/mL reported) 3.

Monitoring Protocol

Critical: Begin glucose monitoring BEFORE first dose and continue intensively during first week:

• Verify fasting glucose before treatment initiation 1
• Schedule outpatient visit on day 4 (end of first dosing cycle) specifically for glucose check - this timing is crucial as severe hyperglycemia can develop asymptomatically 3
• Consider continuous glucose monitoring for high-risk patients 2
• Monitor for ketoacidosis signs: nausea, vomiting, abdominal pain, confusion 1

High-risk patients requiring enhanced monitoring:

• Pre-existing diabetes or glucose intolerance
• Elevated baseline insulin resistance (HOMA-IR)
• Low β-cell function reserve 2

Management Algorithm

For suspected ketoacidosis:

• Withhold capivasertib immediately
• If confirmed, permanently discontinue 1

For hyperglycemia without ketoacidosis:

• Grade 1 (fasting glucose 126-160 mg/dL): Continue capivasertib, initiate lifestyle modifications and home glucose monitoring 1
• Grade 2 (fasting glucose 161-250 mg/dL): Withhold capivasertib, start glucose-lowering agents, resume at reduced dose when improved 1
• Grade 3 (fasting glucose 251-500 mg/dL): Withhold capivasertib, intensive glucose management, resume at reduced dose or discontinue 1
• Grade 4 (fasting glucose >500 mg/dL or life-threatening): Permanently discontinue 1

Preferred glucose-lowering agents:

• SGLT2 inhibitors (empagliflozin) and alpha-glucosidase inhibitors (voglibose) are effective 6
• Avoid insulin-based therapies - they are generally ineffective due to severe insulin resistance and may worsen cancer outcomes 6
• Metformin shows limited efficacy 4

Important caveat: Hyperglycemia improves during drug-free intervals (days 5-7) and metabolic disturbance may partially attenuate with repeated cycles 5.

Diarrhea

Incidence and Timing

• 72% of patients experience diarrhea, 9% grade 3-4 1
• Median onset: 8 days (range 1-519 days)
• Median time to improvement: 4 days for grade ≥2 1

Management Algorithm

At first sign of loose stools:

• Immediately start loperamide 1
• Increase oral fluids aggressively to prevent dehydration 1
• Implement dietary modifications: low-fat, low-fiber diet; minimize fruit, red meat, alcohol, spicy food, caffeine 7

Grade-based management:

• Grade 1 (increase of <4 stools/day): Continue capivasertib, supportive care
• Grade 2 (4-6 stools/day): Withhold capivasertib, loperamide + oral rehydration solution; resume at same or reduced dose when improved to grade ≤1 1
• Grade 3 (≥7 stools/day, hospitalization indicated): Withhold capivasertib, hospitalize for IV fluids; resume at reduced dose or discontinue 1
• Grade 4 (life-threatening): Permanently discontinue 1

Common pitfall: Dehydration can develop rapidly with severe diarrhea - maintain high index of suspicion and low threshold for IV hydration.

Cutaneous Adverse Reactions

Incidence and Spectrum

• 58% of patients develop cutaneous reactions, 17% grade 3-4 1
• Median onset: 13 days (range 1-575 days)
• Includes: rash, palmar-plantar erythrodysesthesia, erythema multiforme (1.7%), DRESS syndrome (0.3%) 1
• 44% require corticosteroid treatment (37% topical, 19% systemic) 1

Management Algorithm

Prophylaxis (start before treatment):

• Regular emollients to all patients 7

Active management:

• Early dermatology consultation is essential - do not delay 1
• Monitor closely during first 6 weeks with bi-weekly visits, then monthly 7

Grade-based approach:

• Grade 1 (rash <10% BSA, no symptoms): Continue capivasertib, topical emollients, monitor closely 1
• Grade 2 (10-30% BSA or symptomatic):
  • If tolerable and brief: continue with topical corticosteroids/antibiotics
  • If prolonged/intolerable: withhold capivasertib, topical ± oral antibiotics, resume at reduced dose 7, 1
• Grade 3 (>30% BSA or severe symptoms): Withhold capivasertib, systemic corticosteroids, dermatology consultation; resume at reduced dose or discontinue 1
• Grade 4 or DRESS/EM: Permanently discontinue 1

Critical warning: DRESS syndrome and erythema multiforme are severe, potentially life-threatening reactions requiring immediate permanent discontinuation.

Additional Adverse Effects

Hematologic (common):

• Decreased lymphocytes (47%), hemoglobin (45%), leukocytes (32%), neutrophils (23%) 1
• Monitor CBC before each cycle

Other frequent effects:

• Nausea (35%), fatigue (35%), vomiting (21%), stomatitis (20%)
• Increased triglycerides (27%), creatinine (22%) 1

Special Population Considerations

Elderly patients (≥65 years):

• Higher risk profile: 57% vs 36% grade 3-5 adverse reactions, 30% vs 15% dose reductions, 23% vs 8% permanent discontinuations 1
• Require more intensive monitoring and lower threshold for dose modification

Drug interactions:

• Avoid strong CYP3A inhibitors (increase capivasertib exposure)
• Avoid strong/moderate CYP3A inducers (decrease effectiveness)
• If moderate CYP3A inhibitor unavoidable: reduce capivasertib dose 1

Key Clinical Pearls

1. Hyperglycemia monitoring must begin BEFORE first dose - waiting for symptoms is too late as ketoacidosis can develop rapidly and asymptomatically 3
2. Day 4 glucose check is non-negotiable - this catches early severe hyperglycemia before it becomes life-threatening 3
3. Diarrhea management is time-sensitive - start loperamide and hydration at first loose stool, not after multiple episodes 1
4. Dermatology should be involved early - waiting for severe reactions increases risk of permanent discontinuation 1
5. Adverse effects follow the dosing cycle - expect improvement during 3-day drug-free intervals 2, 5